title: Optimal blood stem cell mobilization using 10 micrograms/kg granulocyte colony-stimulating factor (G-CSF) alone for high-dose melphalan intensification in multiple myeloma: an intrapatient controlled study.
abstract: A recent randomized multicentric French study has shown that intensification with stem cell rescue improves the response rate and progression-free survival in multiple myeloma. Transplantation with primed peripheral blood stem cells (PBSC) displays a faster hematological recovery, especially for platelets, as compared with a bone marrow stem cell graft. In multiple myeloma, the optimal mobilization method for PBSC is unknown. The present study compares mobilization with cyclophosphamide 4 g/m2 + G-CSF 5 micrograms/kg versus G-CSF 5 micrograms/kg alone versus G-CSF 10 micrograms/kg alone in two cases of multiple myeloma, using an intrapatient controlled evaluation of the amount of CD34-positive cells obtained during each leukapheresis. In both cases, the highest CD34-positive cells yield was obtained with G-CSF at 10 micrograms/kg. Despite the low number of cases, this method, devoid of life-threatening toxicity, might be of greatest interest in multiple myeloma.
authors.affiliation: Clinic of the University of Brussels, Erasme Hospital, Belgium.
authors.forename: W
authors.initials: W
authors.lastname: Feremans
authors.forename: F
authors.initials: F
authors.lastname: Le Moine
authors.forename: C
authors.initials: C
authors.lastname: Ravoet
authors.forename: M
authors.initials: M
authors.lastname: Lambermont
authors.forename: G
authors.initials: G
authors.lastname: Bastin
authors.forename: J P
authors.initials: JP
authors.lastname: Delville
authors.forename: O
authors.initials: O
authors.lastname: Pradier
authors.forename: E
authors.initials: E
authors.lastname: Dupont
authors.forename: P
authors.initials: P
authors.lastname: Capel
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D018952:Antigens, CD34; D001530:Belgium / Q000453:epidemiology; D001803:Blood Transfusion; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology* / Q000627:therapeutic use; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007937:Leukapheresis; D008297:Male; D008558:Melphalan / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000453:epidemiology / Q000628:therapy*
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D008558:Melphalan